Mount Yale Investment Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-106,905
Closed -$241K 428
2020
Q3
$241K Sell
106,905
-195
-0.2% -$557 0.03% 301
2020
Q2
$383K Sell
107,100
-152
-0.1% -$548 0.07% 246
2020
Q1
$408K Sell
107,252
-346
-0.3% -$1.14K 0.09% 212
2019
Q4
$374K Buy
+107,598
New +$280K 0.07% 253

Other funds holding BMY.RT

Mount Yale Investment Advisors's BMY.RT Position: Q4 2020 in Review

Mount Yale Investment Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 106,905 shares — an estimated $241K sold.

Mount Yale Investment Advisors first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $408K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • Mount Yale Investment Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 106,905 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $241K.
  • Mount Yale Investment Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Mount Yale Investment Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $408K in Q1 2020.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Mount Yale Investment Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.